Anika (ANIK) Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]
Anika Therapeutics Inc. (ANIK)
Last anika therapeutics inc. earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anikatherapeutics.com/investor-relations
Company Research
Source: Globe and Mail, The
President and Chief Executive Officer — Cheryl Renee Blanchard, Ph.D. Executive Vice President, Chief Financial Officer and Chief Operating Officer — Stephen D. Griffin Director of Corporate Development and Investor Relations — Matt Hall Takeaways Total Revenue -- $28.2 million, reflecting an 8% decrease, impacted by manufacturing yield challenges and a $900,000 order shortfall in international osteoarthritis (OA) Pain sales. Gross Margin -- 51%, down 16 percentage points, driven by a onetime $3 million noncash charge related to Monovisc and Cingal production yields; excluding this charge, gross margin would have exceeded 60%. Regenerative Solutions Revenue -- Up 41%, led by continued adoption of the Integrity Implant System, which achieved sequential growth for five consecutive quarters and surpassed full-year 2024 revenue by June. OEM Channel Revenue -- $16.3 million, representing a 13% decline, primarily from reduced demand and pricing pressure for Orthovisc and lowe
Show less
Read more
Impact Snapshot
Event Time:
ANIK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIK alerts
High impacting Anika Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ANIK
News
- Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026GlobeNewswire
- Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference [Yahoo! Finance]Yahoo! Finance
- Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.MarketBeat
- Anika Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
ANIK
Earnings
- 2/26/26 - Beat
ANIK
Analyst Actions
- 2/27/26 - Barrington Research
ANIK
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/23/26 - Form 4
- 3/17/26 - Form 4
- ANIK's page on the SEC website